The effect of silymarin on liver enzymes in patients taking isotretinoin: A randomized clinical trial

Abstract

The aim of the present study was to investigate the effect of silymarin (Livergol) on liver enzymes in patients taking isotretinoin (Roaccutane). In this double‐blind clinical trial, 74 patients with acne and taking isotretinoin were randomly assigned into intervention (N = 37) and control (N = 37) groups. The intervention group received a 140 mg Livergol capsule per day for 30 days. The control group received a starch‐containing capsule as a placebo once a day for 30 days. Liver enzyme levels were measured before and after the intervention. The data were analyzed using chi‐square test, Independent t test, paired sample t test and analysis of covariance (ANCOVA). The results showed no statistically significant difference between the intervention and control groups at the beginning of study in levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) (p > .05). At the end of the study, a statistically significant difference was observed between the two groups in levels of AST and ALT (p < .05). Livergol prevented liver enzymes from increasing, so it can be used as an effective, low‐cost, and low‐complication treatment for the problem of increased levels of liver enzymes following the use of isotretinoin.

Protective Effect of Silymarin and Gallic Acid against Cisplatin-Induced Nephrotoxicity and Hepatotoxicity

“…Two different studies examined the protective effect of hyperin against cisplatin-induced liver damage. In the study, it was observed that AST and ALT levels in the serum were significantly increased in the cisplatin-treated group compared with the control group [ 33 , 34 ]. In another study, the protective effect against cisplatin-induced liver and kidney tissue damage was investigated.…”

Effects of silymarin supplementation on liver and kidney functions: A systematic review and dose–response meta‐analysis

“…These were published between 1982 and 2022. Thirty‐nine studies were parallel trials (Abbasirad et al, 2021; Ahmed et al, 2022; Anushiravani et al, 2019; Aryan et al, 2022; Bárcena et al, 2013; Di Pierro et al, 2013; Ebrahimpour Koujan et al, 2015; Elgarf et al, 2015; Fallah Huseini et al, 2005; Fallahzadeh et al, 2012; Firuzi et al, 2016; Fried et al, 2012; Gharagozloo et al, 2009; Hajaghamohammadi et al, 2008; Hashemi et al, 2009; Heo et al, 2017; Huseini et al, 2004, 2006; Kheong et al, 2017; Luangchosiri et al, 2015; Lucena et al, 2002; Masoodi et al, 2013; Mirhashemi et al, 2022; Mirnezami et al, 2020; Mirzaei et al, 2021; Moayedi et al, 2013; Moezian et al, 2022; Mohaghegh et al, 2015; Momeni et al, 2015; Palasciano et al, 1994; Parés et al, 1998; Ramezani et al, 2008; Razzaq et al, 2011; Rendina et al, 2014; Salmi & Sarna, 1982; Simanek et al, 2001; Solhi et al, 2014; Taghvaei et al, 2013; Valentová et al, 2008) and two were crossover studies (Darvishi‐Khezri et al, 2017; Gordon et al, 2006). The duration of the trials and sample sizes varied from 2 to 96 weeks and from 16 to 200 participants, respectively.…”

“…The average age of the participants was between 18 and 67 years. The studies were conducted in Iran (Abbasirad et al, 2021; Anushiravani et al, 2019; Aryan et al, 2022; Darvishi‐Khezri et al, 2017; Ebrahimpour Koujan et al, 2015; Fallah Huseini et al, 2005; Fallahzadeh et al, 2012; Firuzi et al, 2016; Gharagozloo et al, 2009; Hajaghamohammadi et al, 2008; Hashemi et al, 2009; Huseini et al, 2004, 2006; Masoodi et al, 2013; Mirhashemi et al, 2022; Mirnezami et al, 2020; Mirzaei et al, 2021; Moayedi et al, 2013; Moezian et al, 2022; Mohaghegh et al, 2015; Momeni et al, 2015; Ramezani et al, 2008; Solhi et al, 2014; Taghvaei et al, 2013), Australia (Gordon et al, 2006), Finland (Salmi & Sarna, 1982), the United States (Fried et al, 2012), Spain (Bárcena et al, 2013; Lucena et al, 2002; Parés et al, 1998), Italy (Palasciano et al, 1994; Rendina et al, 2014), the Czech Republic (Simanek et al, 2001; Valentová et al, 2008), Malaysia (Kheong et al, 2017), Thailand (Luangchosiri et al, 2015), Egypt (Elgarf et al, 2015), Italy (Di Pierro et al, 2013), South Korea (Heo et al, 2017), Iraq (Razzaq et al, 2011), and Pakistan (Ahmed et al, 2022).…”

Phenolic‐enriched maple syrup extract protects human keratinocytes against hydrogen peroxide and methylglyoxal induced cytotoxicity

“…Therefore, because of their inherent lack of toxicity and natural origin, these polyphenols show great promise for preventive and therapeutic effects against skin aging, skin damage and cutaneous toxicity, including ulcer, burns, and wounds 32 . Moreover, several clinical studies support the skin protective effects of polyphenols and their dermatological applications 33‐35 . The skin protective effects of dietary polyphenols as well as their therapeutic potential for the treatment of skin disorders have been reviewed in several articles 32,36‐38 .…”